Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2021 Dec 21;41(6):1052–1064. doi: 10.1007/s11596-021-2470-7

Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods

Jo-Lewis Banga Ndzouboukou 1, Yan-di Zhang 1, Xiong-lin Fan 1,✉
PMCID: PMC8692081  PMID: 34935114

Abstract

The ongoing Coronavirus disease 19 pandemic has likely changed the world in ways not seen in the past. Neutralizing antibody (NAb) assays play an important role in the management of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak. Using these tools, we can assess the presence and duration of antibody-mediated protection in naturally infected individuals, screen convalescent plasma preparations for donation, test the efficacy of immunotherapy, and analyze NAb titers and persistence after vaccination to predict vaccine-induced protective effects. This review briefly summarizes the various methods used for the detection of SARS-CoV-2 NAbs and compares their advantages and disadvantages to facilitate their development and clinical application.

Key words: Coronavirus disease 19, severe acute respiratory syndrome coronavirus-2, neutralizing antibodies, viral neutralization test, plaque reduction neutralization test, pseudovirus-based neutralization assays, enzyme-linked immunosorbent assay, lateral flow immunoassays

Footnotes

This project was supported by grants from the Applied Basic Research Key Project of Wuhan Municipal Bureau of Science and Technology (2020020601012218) and the Fundamental Research Funds for the Central Universities (HUST COVID-19 Rapid Response Call No. 2020kfyXGYJ040).

Conflict of Interest Statement

We declare that we have no conflicts of interest.

Contributor Information

Jo-Lewis Banga Ndzouboukou, Email: bangas19@yahoo.fr.

Xiong-lin Fan, Email: xlfan@hust.edu.cn.

References

  • 1.Weekly epidemiological update on COVID-19 — 21 September 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-21-september-2021. [Accessed Sep 22, 2021].
  • 2.Tang Q, Song Y, Shi M, et al. Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition. Sci Rep. 2015;5:17155. doi: 10.1038/srep17155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192. doi: 10.1038/s41579-018-0118-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8:S9–S14. doi: 10.1046/j.1440-1843.2003.00518.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Middle East respiratory syndrome coronavirus (MERS-CoV). Available from: https://www.who.int/westernpacific/health-topics/middle-east-respiratory-syndrome-coronavirus-mers. [Accessed September 13, 2021].
  • 6.Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. doi: 10.1016/j.jhin.2020.01.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648. [DOI] [PubMed] [Google Scholar]
  • 9.Yu C, Lei Q, Li W, et al. Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China. Am J Prev Med. 2020;59(2):168–175. doi: 10.1016/j.amepre.2020.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. doi: 10.1038/s41564-020-0695-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(10):2249. doi: 10.1002/jmv.26234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Li C, Yang Y, Ren L. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. Infect Genet Evol. 2020;82:104285. doi: 10.1016/j.meegid.2020.104285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wu A, Peng Y, Huang B, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325–328. doi: 10.1016/j.chom.2020.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wang C, Liu Z, Chen Z, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020;92(6):667–674. doi: 10.1002/jmv.25762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Yoshimoto FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein J. 2020;39(3):198–216. doi: 10.1007/s10930-020-09901-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Chan JFW, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236. doi: 10.1080/22221751.2020.1719902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Vashist SK. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics (Basel) 2020;10(4):E202. doi: 10.3390/diagnostics10040202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi: 10.1126/science.abb2507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Walls AC, Park Y-J, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;183(6):1735. doi: 10.1016/j.cell.2020.11.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Huang Y, Yang C, Xu X-F, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–1149. doi: 10.1038/s41401-020-0485-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi: 10.1126/sciimmunol.abc8413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi: 10.1126/science.abf4063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574. doi: 10.1016/S1473-3099(20)30196-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52):eabe0367. doi: 10.1126/sciimmunol.abe0367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Röltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):eabe0240. doi: 10.1126/sciimmunol.abe0240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–1607. doi: 10.1038/s41564-020-00813-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Tang F, Quan Y, Xin ZT, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186(12):7264–7268. doi: 10.4049/jimmunol.0903490. [DOI] [PubMed] [Google Scholar]
  • 29.Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020;383(11):1085–1087. doi: 10.1056/NEJMc2025179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–1734. doi: 10.1056/NEJMoa2026116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. 2020;53(5):925–933.e4. doi: 10.1016/j.immuni.2020.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Hsueh PR, Huang LM, Chen PJ, et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062–1066. doi: 10.1111/j.1469-0691.2004.01009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.He Z, Dong Q, Zhuang H, et al. Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS. Clin Diagn Lab Immunol. 2004;11(4):792–794. doi: 10.1128/CDLI.11.4.792-794.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995–1007. doi: 10.1016/S0140-6736(15)60454-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26(11):1691–1693. doi: 10.1038/s41591-020-1083-1. [DOI] [PubMed] [Google Scholar]
  • 36.Callow KA, Parry HF, Sergeant M, et al. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435–446. doi: 10.1017/S0950268800048019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Choe PG, Perera R A PM, Park WB, et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis. 2017;23(7):1079–1084. doi: 10.3201/eid2307.170310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Gasser R, Cloutier M, Prévost J, et al. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep. 2021;34(9):108790. doi: 10.1016/j.celrep.2021.108790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi: 10.1093/cid/ciaa344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Long Q-X, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848. doi: 10.1038/s41591-020-0897-1. [DOI] [PubMed] [Google Scholar]
  • 41.Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep Med. 2020;1(3):100040. doi: 10.1016/j.xcrm.2020.100040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773–775. doi: 10.1038/s41423-020-0474-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791–797. doi: 10.1099/jgv.0.001439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236. doi: 10.1038/nrmicro2090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016;3(1):237–261. doi: 10.1146/annurev-virology-110615-042301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Cho H, Excler JL, Kim JH, et al. Development of Middle East Respiratory Syndrome Coronavirus vaccines — advances and challenges. Hum Vaccin Immunother. 2018;14(2):304–313. doi: 10.1080/21645515.2017.1389362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA. 2020;117(13):7001–7003. doi: 10.1073/pnas.2002589117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Zhu Z, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA. 2007;104(29):12123–12128. doi: 10.1073/pnas.0701000104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rockx B, Corti D, Donaldson E, et al. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol. 2008;82(7):3220–3235. doi: 10.1128/JVI.02377-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Du L, Yang Y, Zhou Y, et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017;21(2):131–143. doi: 10.1080/14728222.2017.1271415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhou Y, Yang Y, Huang J, et al. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses. 2019;11(1):E60. doi: 10.3390/v11010060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Poh CM, Carissimo G, Wang B, et al. Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein. bioRxiv, 2020:15461
  • 53.Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175–183. doi: 10.1016/j.virusres.2014.03.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448. doi: 10.1126/science.abb2762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Li Y, Ma ML, Lei Q, et al. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Rep. 2021;34(13):108. doi: 10.1016/j.celrep.2021.108915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Piccoli L, Park YJ, Tortorici MA, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183(4):1024–1042.e21. doi: 10.1016/j.cell.2020.09.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Addetia A, Crawford KHD, Dingens A, et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020;58(11):e02107–e02120. doi: 10.1128/JCM.02107-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Moore JP, Klasse PJ. COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds. J Virol. 2020;94(17):e01083–e01020. doi: 10.1128/JVI.01083-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Zohar T, Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol. 2020;20(7):392–394. doi: 10.1038/s41577-020-0359-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–449. doi: 10.1038/s41586-020-2548-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Lei Q, Hou H, Yu C, et al. Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. J Immunol Res. 2021;2021:9822706. doi: 10.1155/2021/9822706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Cao Y, Su B, Guo X, et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 2020;182(1):73–84.e16. doi: 10.1016/j.cell.2020.05.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Lei Q, Li Y, Hou HY, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021;76(2):551–561. doi: 10.1111/all.14622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Tani H, Kimura M, Tan L, et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virol J. 2021;18:16. doi: 10.1186/s12985-021-01490-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765. doi: 10.1172/JCI138745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469. doi: 10.1038/s41586-020-2196-x. [DOI] [PubMed] [Google Scholar]
  • 69.Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620. doi: 10.1038/s41467-020-15562-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020;11(1):2806. doi: 10.1038/s41467-020-16638-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Theel ES, Slev P, Wheeler S, et al. The Role of Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol. 2020;58(8):e00797–20. doi: 10.1128/JCM.00797-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Lester S, Harcourt J, Whitt M, et al. Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies. Access Microbiol. 2019;1(9):e000057. doi: 10.1099/acmi.0.000057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Degnah AA, Al-Amri SS, Hassan AM, et al. Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011–2016. J Infect Public Health. 2020;13(5):697–703. doi: 10.1016/j.jiph.2020.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Mendoza EJ, Manguiat K, Wood H, et al. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr Protoc Microbiol. 2020;57(1):cp–c105. doi: 10.1002/cpmc.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020;52(6):971–977.e3. doi: 10.1016/j.immuni.2020.04.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680–686. doi: 10.1080/22221751.2020.1743767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Crawford KHD, Eguia R, Dingens AS, et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020;12(5):E513. doi: 10.3390/v12050513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Manenti A, Maggetti M, Casa E, et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J Med Virol. 2020;92(10):2096–2104. doi: 10.1002/jmv.25986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478–1488. doi: 10.3201/eid2607.200841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16):2000421. doi: 10.2807/1560-7917.ES.2020.25.16.2000421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Xiong HL, Wu YT, Cao JL, et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect. 2020;9(1):2105–2113. doi: 10.1080/22221751.2020.1815589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Zettl F, Meister TL, Vollmer T, et al. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines (Basel) 2020;8(3):E386. doi: 10.3390/vaccines8030386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217(11):e20201181. doi: 10.1084/jem.20201181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Xie X, Muruato AE, Zhang X, et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat Commun. 2020;11(1):5214. doi: 10.1038/s41467-020-19055-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Focosi D, Maggi F, Mazzetti P, et al. Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol. 2021;31(2):e2170. doi: 10.1002/rmv.2170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Rosado J, Pelleau S, Cockram C, et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe. 2021;2(2):e60–e69. doi: 10.1016/S2666-5247(20)30197-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Taylor SC, Hurst B, Charlton CL, et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J Clin Microbiol. 2021;59(4):e02438–e02420. doi: 10.1128/JCM.02438-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11(1):4059. doi: 10.1038/s41467-020-17892-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073–1078. doi: 10.1038/s41587-020-0631-z. [DOI] [PubMed] [Google Scholar]
  • 91.Byrnes JR, Zhou XX, Lui I, et al. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. mSphere. 2020;5(5):e00802–e00820. doi: 10.1128/mSphere.00802-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Ferrara F, Temperton N. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis. Methods Protoc. 2018;1(1):8. doi: 10.3390/mps1010008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Mukherjee S, Dowd KA, Manhart CJ, et al. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol. 2014;88(13):7210–7220. doi: 10.1128/JVI.03690-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–456. doi: 10.1038/s41586-020-2571-7. [DOI] [PubMed] [Google Scholar]
  • 95.Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16):200421. doi: 10.2807/1560-7917.ES.2020.25.16.2000421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478–1488. doi: 10.3201/eid2607.200841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Algaissi A, Hashem AM. Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay. Methods Mol Biol. 2020;2099:107–116. doi: 10.1007/978-1-0716-0211-9_9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Haveri A, Smura T, Kuivanen S, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25(11):2000266. doi: 10.2807/1560-7917.ES.2020.25.11.2000266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Conte C, Sogni F, Affanni P, et al. Vaccines against Coronaviruses: The State of the Art. Vaccines (Basel) 2020;8(2):E309. doi: 10.3390/vaccines8020309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Ghaebi M, Osali A, Valizadeh H, et al. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances. J Cell Physiol. 2020;235(12):9098–9109. doi: 10.1002/jcp.29771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv, 2020: 20047365.
  • 102.Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003;41(11):5046–5052. doi: 10.1128/JCM.41.11.5046-5052.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Fu X, Tao L, Zhang X. Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. Mol Ther Methods Clin Dev. 2021;20:350–356. doi: 10.1016/j.omtm.2020.12.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680–686. doi: 10.1080/22221751.2020.1743767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Tang H, Kuhen KL, Wong-Staal F. Lentivirus replication and regulation. Annu Rev Genet. 1999;33:133–170. doi: 10.1146/annurev.genet.33.1.133. [DOI] [PubMed] [Google Scholar]
  • 106.Whitelaw CBA. Transgenic livestock made easy. Trends Biotechnol. 2004;22(4):157–159. doi: 10.1016/j.tibtech.2004.02.005. [DOI] [PubMed] [Google Scholar]
  • 107.Lillico S, Vasey D, King T, et al. Lentiviral transgenesis in livestock. Transgenic Res. 2011;20(3):441–442. doi: 10.1007/s11248-010-9448-8. [DOI] [PubMed] [Google Scholar]
  • 108.Picanco-Castro V, Sousa Russo-Carbolante de E, Tadeu Covas D. Advances in lentiviral vectors: a patent review. Recent Pat DNA Gene Seq. 2012;6(2):82–90. doi: 10.2174/187221512801327433. [DOI] [PubMed] [Google Scholar]
  • 109.Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol. 1998;9(5):457–463. doi: 10.1016/S0958-1669(98)80029-3. [DOI] [PubMed] [Google Scholar]
  • 110.Kumar M, Keller B, Makalou N, et al. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001;12(15):1893–1905. doi: 10.1089/104303401753153947. [DOI] [PubMed] [Google Scholar]
  • 111.Naldini L, Blömer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA. 1996;93(21):11382–11388. doi: 10.1073/pnas.93.21.11382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Reiser J, Harmison G, Kluepfel-Stahl S, et al. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci USA. 1996;93(26):15266–15271. doi: 10.1073/pnas.93.26.15266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Blömer U, Naldini L, Kafri T, et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997;71(9):6641–6649. doi: 10.1128/jvi.71.9.6641-6649.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Kordower JH, Bloch J, Ma SY, et al. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol. 1999;160(1):1–16. doi: 10.1006/exnr.1999.7178. [DOI] [PubMed] [Google Scholar]
  • 115.Blesch A, Tuszynski MH. Transient growth factor delivery sustains regenerated axons after spinal cord injury. J Neurosci. 2007;27(39):10535–10545. doi: 10.1523/JNEUROSCI.1903-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Sinn PL, Sauter SL, McCray PB. Gene Therapy Progress and Prospects: Development of improved lentiviral and retroviral vectors — design, biosafety, and production. Gene Ther. 2005;12(14):1089–1098. doi: 10.1038/sj.gt.3302570. [DOI] [PubMed] [Google Scholar]
  • 117.Sandrin V, Russell SJ, Cosset FL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol. 2003;281:137–178. doi: 10.1007/978-3-642-19012-4_4. [DOI] [PubMed] [Google Scholar]
  • 118.Cannon JR, Sew T, Montero L, et al. Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol. 2011;228(1):41–52. doi: 10.1016/j.expneurol.2010.10.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Cronin J, Zhang XY, Reiser J. Altering the Tropism of Lentiviral Vectors through Pseudotyping. Curr Gene Ther. 2005;5(4):387–398. doi: 10.2174/1566523054546224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992;11(8):3053–3058. doi: 10.1002/j.1460-2075.1992.tb05376.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Wang J, Deng F, Ye G, et al. Comparison of lentiviruses pseudotyped with S proteins from coronaviruses and cell tropisms of porcine coronaviruses. Virol Sin. 2016;31(1):49–56. doi: 10.1007/s12250-015-3690-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Ren W, Qu X, Li W, et al. Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J Virol. 2008;82(4):1899–1907. doi: 10.1128/JVI.01085-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Kobinger GP, Limberis MP, Somanathan S, et al. Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum Gene Ther. 2007;18(5):413–422. doi: 10.1089/hum.2006.194. [DOI] [PubMed] [Google Scholar]
  • 124.Nie Y, Wang P, Shi X, et al. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem Biophys Res Commun. 2004;321(4):994–1000. doi: 10.1016/j.bbrc.2004.07.060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010;58(2):107–119. doi: 10.1007/s00005-010-0063-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263–267. doi: 10.1126/science.272.5259.263. [DOI] [PubMed] [Google Scholar]
  • 127.Kim VN, Mitrophanous K, Kingsman SM, et al. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol. 1998;72(1):811–816. doi: 10.1128/JVI.72.1.811-816.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Parolin C, Dorfman T, Palú G, et al. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol. 1994;68(6):3888–3895. doi: 10.1128/jvi.68.6.3888-3895.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Fouchier RA, Simon JH, Jaffe AB, et al. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol. 1996;70(12):8263–8269. doi: 10.1128/jvi.70.12.8263-8269.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997;15(9):871–875. doi: 10.1038/nbt0997-871. [DOI] [PubMed] [Google Scholar]
  • 131.Klaver B, Berkhout B. Comparison of 5′ and 3′ long terminal repeat promoter function in human immunodeficiency virus. J Virol. 1994;68(6):3830–3840. doi: 10.1128/jvi.68.6.3830-3840.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Yu SF, Rüden von T, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA. 1986;83(10):3194–3198. doi: 10.1073/pnas.83.10.3194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Laspia MF, Rice AP, Mathews MB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell. 1989;59(2):283–292. doi: 10.1016/0092-8674(89)90290-0. [DOI] [PubMed] [Google Scholar]
  • 134.Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–8471. doi: 10.1128/JVI.72.11.8463-8471.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Merten OW, Hebben M, Bovolenta C. Production of lentiviral vectors. Mol Ther Methods Clin Dev. 2016;3:16017. doi: 10.1038/mtm.2016.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Fraga H. Firefly luminescence: a historical perspective and recent developments. Photochem Photobiol Sci. 2008;7(2):146–158. doi: 10.1039/b719181b. [DOI] [PubMed] [Google Scholar]
  • 137.Uckert W, Pedersen L, Günzburg W. Green fluorescent protein retroviral vector: generation of high-titer producer cells and virus supernatant. Methods Mol Med. 2000;35:275–285. doi: 10.1385/1-59259-086-1:275. [DOI] [PubMed] [Google Scholar]
  • 138.Heider S, Metzner C. Quantitative real-time single particle analysis of virions. Virology. 2014;462–463:199–206. doi: 10.1016/j.virol.2014.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139.Geraerts M, Willems S, Baekelandt V, et al. Comparison of lentiviral vector titration methods. BMC Biotechnol. 2006;6:34. doi: 10.1186/1472-6750-6-34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140.Case JB, Rothlauf PW, Chen RE, et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe. 2020;28(3):475–485.e5. doi: 10.1016/j.chom.2020.06.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Almahboub SA, Algaissi A, Alfaleh MA, et al. Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay. Front Microbiol. 2020;11:2020. doi: 10.3389/fmicb.2020.02020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142.Gan SD, Patel KR. Enzyme immunoassay and enzyme-linked immunosorbent assay. J Invest Dermatol. 2013;133(9):e12. doi: 10.1038/jid.2013.287. [DOI] [PubMed] [Google Scholar]
  • 143.Zhang N, Chen S, Wu J, et al. A lateral flow test detecting SARS-CoV-2 neutralizing antibodie. Available from: https://europepmc.org/article/PPR/PPR236206. 2020; [Accessed Aug 5, 2021].
  • 144.Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA) Clin Chem. 2005;51(12):2415–2418. doi: 10.1373/clinchem.2005.051532. [DOI] [PubMed] [Google Scholar]
  • 145.Banga Ndzouboukou JL, Zhang Y, Lei Q, et al. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. Curr Med Sci. 2021;6:1–8. doi: 10.1007/s11596-021-2461-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146.Schöler L, Le-Trilling VTK, Eilbrecht M, et al. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds. Front Immunol. 2020;11:573526. doi: 10.3389/fimmu.2020.573526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147.Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem. 2016;60(1):111–120. doi: 10.1042/EBC20150012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Mboowa G. Current and emerging diagnostic tests available for the novel COVID-19 global pandemic. AAS Open Res. 2020;3:8. doi: 10.12688/aasopenres.13059.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149.Parolo C, Escosura-Muñiz de la A, Merkoçi A. Enhanced lateral flow immunoassay using gold nanoparticles loaded with enzymes. Biosens Bioelectron. 2013;40(1):412–416. doi: 10.1016/j.bios.2012.06.049. [DOI] [PubMed] [Google Scholar]
  • 150.Xu M, Wang D, Wang H, et al. COVID-19 diagnostic testing: Technology perspective. Clin Transl Med. 2020;10(4):e158. doi: 10.1002/ctm2.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 151.Russo A, Minichini C, Starace M, et al. Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review. Infect Drug Resist. 2020;13:2657–2665. doi: 10.2147/IDR.S264020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Choudhary S, Sreenivasulu K, Mitra P, et al. Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19. Ann Lab Med. 2021;41(2):129–138. doi: 10.3343/alm.2021.41.2.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153.Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516. doi: 10.1136/bmj.m2516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154.Yun S, Ryu JH, Jang JH, et al. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays. Ann Lab Med. 2021;41(6):577–587. doi: 10.3343/alm.2021.41.6.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155.Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020;92(9):1518–1524. doi: 10.1002/jmv.25727. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Current Medical Science are provided here courtesy of Nature Publishing Group

RESOURCES